PRAX Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Praxis Precision Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.76 |
| 52 Week High | US$86.93 |
| 52 Week Low | US$14.25 |
| Beta | 2.69 |
| 11 Month Change | -3.11% |
| 3 Month Change | 35.78% |
| 1 Year Change | 364.47% |
| 33 Year Change | -74.38% |
| 5 Year Change | n/a |
| Change since IPO | -82.79% |
Recent News & Updates
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30
Recent updates
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10Shareholder Returns
| PRAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.9% | -10.9% | -2.2% |
| 1Y | 364.5% | 13.9% | 30.1% |
Return vs Industry: PRAX exceeded the US Biotechs industry which returned 20.8% over the past year.
Return vs Market: PRAX exceeded the US Market which returned 32.3% over the past year.
Price Volatility
| PRAX volatility | |
|---|---|
| PRAX Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PRAX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 82 | Marcio De'Souza | praxismedicines.com |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF.
Praxis Precision Medicines, Inc. Fundamentals Summary
| PRAX fundamental statistics | |
|---|---|
| Market cap | US$1.43b |
| Earnings (TTM) | -US$151.02m |
| Revenue (TTM) | US$1.61m |
833.3x
P/S Ratio-8.9x
P/E RatioIs PRAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRAX income statement (TTM) | |
|---|---|
| Revenue | US$1.61m |
| Cost of Revenue | US$114.51m |
| Gross Profit | -US$112.91m |
| Other Expenses | US$38.11m |
| Earnings | -US$151.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.10 |
| Gross Margin | -7,034.77% |
| Net Profit Margin | -9,409.22% |
| Debt/Equity Ratio | 0% |
How did PRAX perform over the long term?
See historical performance and comparison